Tandem Diabetes Care (TNDM) Free Cash Flow Growth (3y) (2016 - 2026)
Tandem Diabetes Care (TNDM) Free Cash Flow Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 6.28% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 9.63% |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 0.05% |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 29.36% |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | -27.72% |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 77.20% |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -29.89% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | -0.27% |
| 10 | Tandem Diabetes Care | 1.17 Bn | 597.96 Mn | 136.79 Mn | 29.59% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29.59% |
| Dec 31, 2025 | -17.72% |
| Sep 30, 2025 | -29.31% |
| Jun 30, 2025 | -47.68% |
| Mar 31, 2025 | -53.36% |
| Dec 31, 2024 | 13.98% |
| Sep 30, 2024 | -14.24% |
| Jun 30, 2024 | -34.84% |
| Mar 31, 2024 | -33.72% |
| Dec 31, 2023 | -41.00% |
| Sep 30, 2023 | 57.89% |
| Jun 30, 2023 | -38.27% |
| Mar 31, 2023 | 0.30% |
| Dec 31, 2022 | -24.00% |
| Sep 30, 2022 | 31.57% |
| Jun 30, 2022 | 23.79% |
| Mar 31, 2022 | 72.21% |
| Dec 31, 2021 | 4.99% |
| Sep 30, 2021 | 112.85% |
| Jun 30, 2021 | 81.11% |